CN107998396A - A kind of target spot of oncotherapy and its application - Google Patents

Abstract

Target spot and its application the invention discloses a kind of oncotherapy.The present invention is experimentally confirmed：LSECtin, BTN3A2 and BNT3A3 are embodied in the promotion promoted in the formation of tumour cell ball, the expression of dryness transcription factor and mouse tumor model to tumor progression by promoting the maintenance of tumour cell dryness to promote tumor progression；Tumor progression can effectively be slowed down by suppressing LSECtin and BTN3A2 and BTN3A3 interactions, and being embodied in reduces Tumor incidence and slow down gross tumor volume growth.

Description

A kind of target spot of oncotherapy and its application

Technical field

The invention belongs to biological technical field, and in particular to a kind of target spot of oncotherapy and its application.

Background technology

Global tumor incidence is in rising trend always since the late 1970s.At present for the treatment of breast cancer Means mainly include operation, radiotherapy, chemotherapy, endocrine therapy, Biological target therapy and traditional Chinese medicine auxiliary treatment etc., perplex tumour The root problem for the treatment of is the recurrence after resistance and healing to medicine.Research shows, the basic original of the resistance to the action of a drug and recurrence Because being the lifting of tumour cell dryness.For example, with estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor The triple negative breast cancer that body 2 (HER2) feminine gender is characterized often is considered the tumour dryness for possessing higher.Also research knot Fruit shows that most of non-three negative breast cancer patients, are often recurred in the form of triple negative breast cancer, this is to cause recurrence breast Adenocarcinoma tumor has the reason for more high drug-resistance, stronger transfer ability.However, since triple negative breast cancer suffers for want of medical supplies target spot, There is presently no the therapeutic scheme for curing triple negative breast cancer.

The dryness of tumour is by three diversity of gene, epigenetic and tumor microenvironment factor regulation and control.Due to tumour Cell is there are height heterogeneity, therefore, from gene diversity and epigenetic angle, it is difficult to propose effective treatment side Case.In contrast, the immunocyte of tumor microenvironment infiltration is made by maintenance of the reciprocation to tumour cell dryness with promoting With because it has become with stronger application prospect the hot spot of research.Basic principle based on immunotherapy of tumors, for exempting from The interactive targeted drug of epidemic disease cells against tumor cells, is expected to applied immunology principle and method, improves exempting from for tumour cell The sensitiveness of epidemic focus and pairing effect cell killing, excitation and enhancing antitumor immunity of organism response, cooperate with body immune system, So as to suppress the growth, transfer and recurrence of tumour.

LSECtin (Liver Sinusoidal Endothelial Cells lectin) is II type transmembrane glycoprotein, position It is the newcomer of c-type lectin family in mankind 19p13.3.

BTN3A2 (Butyrophilin subfamily 3member A2) and BTN3A3 (Butyrophilin 3 member A3 of subfamily) it is I type transmembrane glycoprotein, it is the member of B7 superfamilies positioned at mankind 6p22.2.

The content of the invention

It is an object of the present invention to provide the new application for the material for suppressing BTN3A expression and/or activity.

The present invention provides the material for suppressing BTN3A expression and/or activity to prepare with least one in following (1)-(5) Application in the product of kind function：

(1) treatment and/or pre- preventing tumor；

(2) growth of tumour cell is suppressed；

(3) maintenance or promotion of tumour cell dryness are suppressed；

(4) expression of tumour cell dryness correlated characteristic molecule is suppressed；

(5) inside tumor cells STAT3 phosphorylations are suppressed；

The BTN3A is following a1) or a2)：

a1)BTN3A3；

A2) BTN3A2 and BTN3A3.

In above application, the material of the suppression BTN3A expression and/or activity is following any：Disturb BTN3A2 and The RNA molecule of BTN3A3 expression, anti-LSECtin antibody, LSECtin micromolecular inhibitors, LSECtin soluble proteins, interference The RNA molecule of LSECtin expression, anti-BTN3A2 antibody, BTN3A2 micromolecular inhibitors, BTN3A2 soluble proteins, interference RNA molecule, anti-BTN3A3 antibody, BTN3A3 micromolecular inhibitors, BTN3A3 soluble proteins and the interference of BTN3A2 expression The RNA molecule of BTN3A3 expression.

In above application, what the RNA molecule of the interference BTN3A2 and BTN3A3 expression and the interference BTN3A3 were expressed RNA molecule is following b1)-b4)：

B1) the shRNA molecule shown in sequence 4；

B2) sequence 4 is deleted or increases or change one or several nucleotide, and with the nucleotide of 4 identical function of sequence；

B3) the shRNA molecule shown in sequence 5；

B4) sequence 5 is deleted or increases or change one or several nucleotide, and with the nucleotide of 5 identical function of sequence.

In above application, the tumour cell dryness correlated characteristic molecule for Oct4 genes and/or Nanog genes and/or Sox genes.

In above application, the growth for suppressing tumour cell is embodied in the tumor formation rate for reducing tumour cell and/or reduction The volume of tumour cell.

In above application, the product is medicine.

In above application, the tumour is following c1) or c2)：

C1) the tumour of BTN3A3 expression；

C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression；

The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.

It is a further object to provide a kind of product.

The active ingredient of product provided by the invention is expressed for suppression BTN3A and/or the material of activity, the use of the product Way is at least one of following (1)-(5)：

(1) treatment and/or pre- preventing tumor；

(2) growth of tumour cell is suppressed；

(3) maintenance or promotion of tumour cell dryness are suppressed；

(4) expression of tumour cell dryness correlated characteristic molecule is suppressed；

(5) inside tumor cells STAT3 phosphorylations are suppressed；

The BTN3A is following a1) or a2)：

a1)BTN3A3；

A2) BTN3A2 and BTN3A3.

In the said goods, the material of the suppression BTN3A expression and/or activity is following any：Disturb BTN3A2 and The RNA molecule of BTN3A3 expression, anti-LSECtin antibody, LSECtin micromolecular inhibitors, LSECtin soluble proteins, interference The RNA molecule of LSECtin expression, anti-BTN3A2 antibody, BTN3A2 micromolecular inhibitors, BTN3A2 soluble proteins, interference RNA molecule, anti-BTN3A3 antibody, BTN3A3 micromolecular inhibitors, BTN3A3 soluble proteins and the interference of BTN3A2 expression The RNA molecule of BTN3A3 expression.

In the said goods, what the RNA molecule of the interference BTN3A2 and BTN3A3 expression and the interference BTN3A3 were expressed RNA molecule is following b1)-b4)：

B1) the shRNA molecule shown in sequence 4；

B2) sequence 4 is deleted or increases or change one or several nucleotide, and with the nucleotide of 4 identical function of sequence；

B3) the shRNA molecule shown in sequence 5；

B4) sequence 5 is deleted or increases or change one or several nucleotide, and with the nucleotide of 5 identical function of sequence.

In the said goods, the tumour cell dryness correlated characteristic molecule for Oct4 genes and/or Nanog genes and/or Sox genes.

In the said goods, the growth for suppressing tumour cell is embodied in the tumor formation rate for reducing tumour cell and/or reduction The volume of tumour cell.

In the said goods, the product is medicine.

In the said goods, the tumour is following c1) or c2)：

C1) the tumour of BTN3A3 expression；

C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression；

The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.

Final object of the present invention is to provide the new application of BTN3A2 and/or BTN3A3 as target spot.

The present invention provides applications of the BTN3A2 and/or BTN3A3 as target spot in immunotherapy of tumors.

Present invention also offers BTN3A2 and/or BTN3A3 as target spot develop or design immunotherapy of tumors medicine in Application.

In above application, the product is medicine.

In above application, the tumour is following c1) or c2)：

C1) the tumour of BTN3A3 expression；

C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression；

The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.

In above application or product,

The LSECtin for it is following 1) or 2)：

1) protein being made of the amino acid sequence shown in sequence in sequence table 1；

2) amino acid sequence of sequence 1 is passed through to the substitution and/or missing and/or addition of one or several amino acid residues And the protein as derived from sequence 1 with identical function.

The BTN3A2 for it is following 1) or 2)：

1) protein being made of the amino acid sequence shown in sequence in sequence table 2；

2) amino acid sequence of sequence 2 is passed through to the substitution and/or missing and/or addition of one or several amino acid residues And the protein as derived from sequence 2 with identical function；

The BTN3A3 for it is following 1) or 2)：

1) protein being made of the amino acid sequence shown in sequence in sequence table 3；

2) amino acid sequence of sequence 3 is passed through to the substitution and/or missing and/or addition of one or several amino acid residues And the protein as derived from sequence 3 with identical function.

The present invention is experimentally confirmed：LSECtin, BTN3A2 and BNT3A3 are by promoting the maintenance of tumour cell dryness to promote Into tumor progression, it is embodied in and promotes tumour cell ball to be formed, in the expression of dryness transcription factor and mouse tumor model Promotion to tumor progression；Tumor progression can effectively be slowed down by suppressing the interaction of LSECtin and BTN3A2 and BTN3A3, be had Body, which is embodied in reduce Tumor incidence and slow down gross tumor volume, to be increased.

Brief description of the drawings

Fig. 1 is clinical sample tumor cells expression BTN3A3.Fig. 1 (a) is in flow cytometer detection breast cancer patients tumor tissues Tumor cells expression is horizontal；Fig. 1 (b) is that tumor cells expression is horizontal in flow cytometer detection lung cancer patient tumor tissues；Fig. 1 (c) is Tumor cells expression is horizontal in flow cytometer detection colon cancer patient tumor tissues；Fig. 1 (d) swells for flow cytometer detection giant cell tumor of bone patient Tumor cells expression is horizontal in tumor tissue；Fig. 1 (e) is that tumor cells expression is horizontal in flow cytometer detection kidney patient's tumor tissues； Fig. 1 (f) is that tumor cells expression is horizontal in flow cytometer detection carcinoma of parotid gland patient's tumor tissues.

Fig. 2 expresses BTN3A3 for kinds of tumor cells system.Fig. 2 (a) expresses BTN3A3 for a variety of breast cancer cell lines；Fig. 2 (b) BTN3A3 is expressed for a variety of liver cancer cell lines；Fig. 2 (c) expresses BTN3A3 for human melanoma cell line；Fig. 2 (d) is a variety of Gastric carcinoma cell lines express BTN3A3；Fig. 2 (e) expresses BTN3A3 for colon carcinoma cell line.

Fig. 3 is expression of the BTN3A2 and BTN3A3 on breast cancer cell.Fig. 3 (a) shows that breast cancer is thin for qPCR detections Born of the same parents are expression BTN3A2 and BTN3A3；Fig. 3 (b) shows that BTN3A is expressed in breast cancer cell surface for fluidic cell；Fig. 3 (c) is Cellular immunofluorescence detects BTN3A3 and is positioned in breast cancer cell skin covering of the surface.

Fig. 4 is that the BTN3A3 of tumor cells expression promotes tumour to be formed.Fig. 4 (a) is the mRNA water of BTN3A3 and BTN3A2 Flat expression quantity detection；The protein expression amount that Fig. 4 (b) is BTN3A3 detects；Fig. 4 (c) is 231- in people-model in nude mice NC and 231-sh4 are into knurl volume vs；231-NC is contrasted with 231-sh4 tumor formation rates in Fig. 4 (d) people-model in nude mice.

Fig. 5 is that there are direct and specific interaction by the BTN3A3 of LSECtin and tumor cells expression.；Fig. 5 (a) For the BTN3A3 of people source LSECtin and tumor cells expression, there are direct and specific interaction；Fig. 5 (b) is mouse source There are direct and specific interaction by the BTN3A3 of LSECtin and tumor cells expression.

Fig. 6 is LSECtin by promoting tumour cell dryness with the BTN3A3 of tumor cells expression interactions.Fig. 6 (a) Promote tumour cell MDA-MB-231 ball Forming abilities with Fig. 6 (b) for LSECtin/BTN3A3；Fig. 6 (c) for LSECtin with BTN3A3 interactions promote the up-regulation of tumour cell dryness transcription factor.

Fig. 7 be the BTN3A3 interactions of LSECtin and tumor cells expression promote in tumour cell STAT3 phosphorylations into And tumour cell dryness is promoted to maintain result.Fig. 7 (a) promotes tumour cell STAT3 phosphorylations for LSECtin/BTN3A3, but right Other STAT molecules are without activation；Fig. 7 (b) can block LSECtin/BTN3A3 to promote tumour thin to suppress STAT3 inhibitor Born of the same parents' balling-up effect.

Embodiment

Experimental method used in following embodiments is conventional method unless otherwise specified.

The materials, reagents and the like used in the following examples, is commercially available unless otherwise specified.

Quantitative test in following embodiments, is respectively provided with three repeated experiments, and results are averaged.

RNA extracts kits, cDNA reverse transcription reagent box (A3500) and Mix (A6001) in following embodiments are The product of Promega companies.

Cell counting count board (145-0011) in following embodiments is the product of Biorad companies.

CCK8 Cell counting Kits (CK04) in following embodiments are the products of eastern Renhua scientific ＆ technical corporation.

LSECtin (QT01034446), BTN3A2 (QT00060039) and BTN3A3 in following embodiments (QT00060039) qPCR primers are the synthesis of Qiagen companies.

4-6 weeks Female nude mice in following embodiments is the product for tieing up company of tonneau China.

Clostridiopetidase A IV (C5138) in following embodiments is the product of Sigma companies.

DNase I in following embodiments is the product of Xi Meijie companies.

Confining liquid in following embodiments：Solvent is water, solute Na₂HPO₄、KH₂PO₄, NaCl and skim milk；Solute Na₂HPO₄、KH₂PO₄, the concentration of NaCl and skim milk in confining liquid be respectively 0.02M, 0.0015M, 0.14M and 3% (matter Measure percentage composition).

Human breast cancer cell MDA-MB-231 in following embodiments is purchased from National Laboratory cellular resources shared platform, and presses The training method culture provided according to the platform.The condition of culture of human breast cancer cell line MDA-MB-231 is to contain 10% tire Cow's serum (Gibico, article No.：RPMI 1640 culture medium (Thermofish, article No. 10100-147-FBS)： SH30809.01B 37 DEG C in), 5%CO₂It is incubated.

Mouse anti human LSECtin antibody CCB059 in following embodiments is in document " Zhao D, Han X, Zheng X, et al.Correction:The Myeloid LSECtin Is a DAP12-Coupled Receptor That Is Crucial for Inflammatory Response Induced by Ebola Virus Glycoprotein[J].PLoS Pathogens, mistake disclosed in 2016,12 (3) ", the public can obtain from Military Medical Science Institute.

Rabbit anti-mouse LSECtin in following embodiments resists in document " Xu F, Liu J, Liu D, et more al.LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses[J].Cancer research,2014,74(13):3418- Mistake disclosed in 3428. ", the public can obtain from Military Medical Science Institute.

Mouse source LSECtin-Fc in following embodiments is in document " Tang L, Yang J, Tang X, et al.The DC- SIGN family member LSECtin is a novel ligand of CD44on activated T cells[J] .European journal of immunology,2010,40(4):Mistake disclosed in 1185-1191. ", the public can cure from military affairs Subject institute obtains.

Embodiment 1, various clinical sample tumor cells expression BTN3A2 and BTN3A3

First, the separation of clinical sample tumour cell

(1) preparation of digestive juice：By 1640 culture mediums (Hyclone companies, SH30809), the 20mg clostridiopetidase As IV of 20ml And 1mg DNase I are mixed, digestive juice, 0.45 μm of membrane filtration are obtained.

(2) fresh clinical patient tumor tissues are taken respectively, after shredding, are put into the digestive juice of step (1) preparation, are swollen Knurl digestive juice, 37 DEG C of digestion 40min.

(3) with 70 μm of strainer filtering tumour digestive juice, 250g centrifugations 10min.

(4) tumour cell 3 times in tumour digestive juice is cleaned with 1640 culture mediums, tumour is obtained by airflow classification respectively Cell enrichment subgroup：Comprise the following steps that：Living cells group is passed sequentially through into SSC-H/FSC-W and SSC-W/FSC-H and removes adhesion Cell, SSC-A and FSC-A remove cell fragment, CD45- obtains tumor cell enrichment subgroup, and resists by using anti-CD277 Body (antibody identifies BTN3A1, BTN3A2, BTN3A3 of form membrane at the same time) carries out BTN3A detection of expression.

2nd, in breast cancer patients tumor tissues tumour cell BTN3A expressions detection

According to the description in above-mentioned one, tumour cell BTN3A expressions in breast cancer patients tumor tissues are examined Survey.

As a result as shown in Fig. 1 (a)：With CD45^-The breast cancer tumor cells surface expression BTN3A of definition.

3rd, in lung cancer patient tumor tissues tumour cell BTN3A expressions detection

According to the description in above-mentioned one, tumour cell BTN3A expressions in lung cancer patient tumor tissues are detected.

As a result as shown in Fig. 1 (b)：With CD45^-The lung cancer tumor cellular portions surface expression BTN3A of definition.

4th, in colon cancer patient tumor tissues tumour cell BTN3A expressions detection

According to the description in above-mentioned one, tumour cell BTN3A expressions in colon cancer patient tumor tissues are examined Survey.

As a result as shown in Fig. 1 (c)：With CD45^-The colon cancer tumours cellular portions surface expression BTN3A of definition.

5th, in giant cell tumor of bone patient tumor tissues tumour cell BTN3A expressions detection

According to the description in above-mentioned one, to tumour cell BTN3A expressions in giant cell tumor of bone patient's tumor tissues into Row detection.

As a result as shown in Fig. 1 (d)：With CD45^-The giant cell tumor of bone tumour cell part surface expression BTN3A of definition.

6th, in kidney patient tumor tissues tumour cell BTN3A expressions detection

According to the description in above-mentioned one, tumour cell BTN3A expressions in kidney patient's tumor tissues are detected.

As a result as shown in Fig. 1 (e)：With CD45^-The renal cancer tumor cellular portions surface expression BTN3A of definition.

7th, in carcinoma of parotid gland patient tumor tissues tumour cell BTN3A expressions detection

According to the description in above-mentioned one, tumour cell BTN3A expressions in carcinoma of parotid gland patient's tumor tissues are examined Survey.

As a result as shown in Fig. 1 (f)：With CD45^-The carcinoma of parotid gland tumour cell part surface expression BTN3A of definition.

Embodiment 2, kinds of tumor cells system expression BTN3A3

1st, the culture of tumor cell line

Cultivate following breast cancer cell line：MCF7(3111C0001CCC000013)、ZR75-1 (3111C0001CCC000090)、BT474(3111C0001CCC000129)、T47D(3111C0001CCC000265)、MDA- MB-453(3111C0001CCC000016)、SKBR3(3111C0001CCC000085)、MDA-MB-468 (3111C0001CCC000249)、MDA-MB-436(3111C0001CCC000352)；MDA-MB-231 (3111C0001CCC000013)；Liver cancer cell lines：BEL-7402(3131C0001000700010)、HepG2 (3111C0001CCC000035)、HCC-LM3(3142C0001000000316)、HHCC(3111C0002000000069)、 Hep3B(3111C0001CCC000376)、QGY7701(3131C0001000700042)、SMCC7721 (3111C0001CCC000087)、Huh7(3131C0001000700182)；K-1735：A875 (3111C0001CCC000094)、A375(3131C0001000700004)；Gastric carcinoma cell lines：MKN28 (3111C0001CCC000482)、NCI-N87(3111C0001CCC000481)、MGC-803(3111C0001CCC000227)、 SGC-7901(3131C0001000700046)；Colon carcinoma cell line：LOVO(3111C0001CCC000164)、SW480 (3142C0001000000064)、LS174T(3111C0001CCC000248)、DLD-1(3131C0001000700134).On State cell and be purchased from National Laboratory cellular resources shared platform.Above-mentioned cell culture condition is by " National Laboratory cellular resources are shared The method culture of platform " query site.

2nd, above-mentioned each cell line is cracked respectively with RIPA lysates (Thermofisher, 89901), is obtained respectively Cell pyrolysis liquid is obtained, and Western Blot detections are carried out to cell pyrolysis liquid respectively, passes through anti-BTN3A3 antibody (Sigma, HPA007904) detects BTN3A3 expressions.

As a result as shown in Fig. 2 (a)-(e)：It can be seen from the figure that kinds of tumor cells system expresses BTN3A3.

The expression of embodiment 3, BTN3A2 and BTN3A3 on breast cancer cell

First, qPCR detects the expression that breast cancer cell fastens BTN3A2 and BTN3A3

1st, the extraction of RNA and the reverse transcription of cDNA

Following each breast cancer cell is extracted using RNA extracts kits：MCF7、ZR75-1、BT474、T47D、SKBR3、 The RNA of MDA-MB-468, MDA-MB-231, MDA-MB-436；CDNA is synthesized according to the method for cDNA synthetic agent box.

2nd, qPCR detects breast cancer cell and fastens BTN3A3 expressions

The cDNA obtained using step 1 is expanded as template using real time fluorescent quantitative nucleic acid amplification detecting system (qPCR) BTN3A2, BTN3A3 and GAPDH, and pass through software analysis BTN3A2, BTN3A3 relative expression quantities.Above-mentioned BTN3A2, BTN3A3 And GAPDH primers are purchased from Qiagen companies.

As a result as shown in Fig. 3 (a).QPCR testing results show：Breast cancer cell MDA-MB-231, MDA-MB-468, The upper high expression BTN3A2 and BTN3A3 of MDA-MB-436.

2nd, fluidic cell shows BTN3A developed by molecule in breast cancer cell surface

With anti-CD277 antibody (antibody identifies BTN3A1, BTN3A2, BTN3A3 of form membrane at the same time) to following breast Gland cell system：MCF7, ZR75-1, BT474, MDA-MB-468, MDA-MB-231, MDA-MB-436 carry out flow cytometer detection.Tool Body step is as follows：Experimental group is with 1 × PBS with 1:50 volume ratios dilution anti-CD277 antibody (eBioscience, 14-2779), Control group is with 1 × PBS with 1:50 volume ratios dilution isotype control Ab (eBioscience, 14-4714-82), 4 DEG C of incubations 30min.After washing cell 3 times with 1 × PBS, supernatant is abandoned.With 1:50 volume ratios dilute sheep anti-Mouse PE mark fluorescent secondary antibodies (Biolegend, 405307) marks cell, 4 DEG C of incubation 30min.After washing cell 3 times with 1 × PBS, supernatant is abandoned, with 300 μ l PBS carries out flow cytometer detection after being resuspended.

As a result as shown in Fig. 3 (b), as can be seen from the figure：BTN3A is expressed in breast cancer cell MDA-MB-468, MDA- The surface of MB-231 and MDA-MB-436.

3rd, cellular immunofluorescence detection BTN3A3 is positioned in breast cancer cell skin covering of the surface

The MDA-MB-231 cells under cultivation conditions are collected, is washed three times with PBS, washes away unnecessary serum.Dilute the permeable membrane of 10X Liquid (being up to section, 421002) into 1 × working solution.Fixed cell is resuspended with permeable membrane liquid, 350g centrifugation 10min, abandon supernatant, repeat The step is once.The cell after fixed rupture of membranes is resuspended in 100ul permeable membranes liquid, with permeable membrane liquid with 1:The diluted anti-of 200 volume ratios BTN3A3 antibody (Sigma, HPA007904), 4 DEG C of incubation 30min.After washing cell 3 times with permeable membrane liquid, supernatant is abandoned.Add with body Product ratio 1:200 diluted rabbit TRITC fluorescence antibodies (Zhong Shan Golden Bridge, ZF-0318), 4 DEG C of lucifuges are incubated 30min.Washed with permeable membrane liquid Cell three times after, cell is put into glass slide, fluorescence microscopy Microscopic observation BTN3A3 expressions.

As a result as shown in Fig. 3 (c), as can be seen from the figure：MDA-MB-231 cells express BTN3A3, and are primarily targeted for Cell membrane.

Embodiment 4, the BTN3A2 of tumor cells expression and BTN3A3 promote tumour to be formed

Utilize the influence of 231-NC cells and the BTN3A3 of 231-sh4 cells verification tumour expression to tumor progression.Specifically Step is as follows：

1st, the structure of the human breast cancer cell MDA-MB-231 of low BTN3A3 is struck

231-sh3 cells and 231-sh4 cells are stable enhanced green fluorescent protein and strike people's mammary gland of low BTN3A3 Cancer cell MDA-MB-231,231-NC cell is the human breast cancer cell MDA-MB-231 for stablizing enhanced green fluorescent protein.Tool Body construction step is as follows

(1) entrust Suzhou Ji Ma companies complete strike low BTN3A3 the structure of sh expression plasmids and the packaging of slow virus with it is pure The step of change.Sh RNA sequences are as follows：sh3：GCCACAGATGGATCTCATATC (sequence 4)；sh4： CCCTTCTGCAACAACCAATCA (sequence 5)；NC (negative control sequence)：TTCTCCGAACGTGTCACGTTTC.

(2) using slow virus respectively by sh3 expression plasmids transfection aim cell (the human breast cancer cell MDA-MB- of structure 231), and by fluorescin screened, obtain striking the stable cell lines 231-sh3 of low BTN3A3.

Using slow virus respectively by sh4 expression plasmids transfection aim cell (the human breast cancer cell MDA-MB- of structure 231), and by fluorescin screened, obtain striking the stable cell lines 231-sh4 of low BTN3A3.

The NC expression plasmids of structure are transfected into aim cell (human breast cancer cell MDA-MB-231) respectively using slow virus, And screened by fluorescin, obtain control cell lines 231-NC.

Above-mentioned transfection comprises the following steps that：When 18-24 is small before virus transfection, by attached cell with 1 × 10⁵A/hole paving Into 24 orifice plates.It is 2 × 10 to make quantity of the cell in slow-virus transfection⁵MOI/ holes or so.Second day, with containing 6 μ g/ml The 2ml fresh cultures of polybrene (Suzhou Ji Ma companies) replace former culture medium, add appropriate viral suspension.Continue to cultivate 24 it is small when, with fresh culture replace contain virulent culture medium.Visible obvious luciferase expression after when virus infection 48 is small, 72 is small When after it is more obvious.Expand culture one week, the cell with GFP is obtained by airflow classification.

(3) the mRNA level in-site expression quantity detection of BTN3A3 and BTN3A2

10 are collected respectively⁵A 231-sh4 cells and 231-NC control cells, using qPCR respectively to 231-sh4 cells and The BTN3A1 of 231-NC control cells, BTN3A2, BTN3A3mRNA horizontal expressions are detected.Comprise the following steps that：According to examination Method shown in agent box specification carries out RNA extractions and reverse transcription, and the cDNA of acquisition, recycles qPCR primers to carry out qPCR.Wherein, The small extraction reagent kits of RNA (74034) are purchased from Qiagen companies.RNA reverse transcription reagent box (Promega) is purchased from Promega companies. BTN3A1 (QF00264803), BTN3A2 (QT00060039), BTN3A3 (QF00264803) gene qPCR primers are purchased from Qiagen companies.

Shown in testing result such as Fig. 4 (a), compared with control cell 231-NC, the stable cell lines 231- of low BTN3A3 is struck In sh4, the relative expression quantity of BTN3A2 and BTN3A3 are below 0.4, illustrate to strike in the stable cell lines 231-sh4 of low BTN3A3 BTN3A2 and BTN3A3 expressions substantially reduce.

(4) the protein expression amount detection of BTN3A3

10 are collected respectively⁵A 231-sh3 cells, 231-sh4 cells and 231-NC control cells, to 231-sh3 cells, 231-sh4 cells and the BTN3A3 protein expressions of 231-NC control cells are detected.Comprise the following steps that：Split with RIPA Solution liquid (Thermofisher, 89901) is respectively cracked above-mentioned each cell line, obtains cell pyrolysis liquid respectively, and divide It is other that Western Blot detections are carried out to cell pyrolysis liquid, detected by anti-BTN3A3 antibody (Sigma, HPA007904) BTN3A3 expressions, specific method reference antibody specification.

As a result as shown in Fig. 4 (b), compared with control cell 231-NC, strike low BTN3A3 stable cell lines 231-sh3 and Striking BTN3A3 expressions in the stable cell lines 231-sh4 of low BTN3A3 substantially reduces.

2nd, respectively by control cell 231-NC and 231-sh4 cell with a 1000 cells/plantation nude mice mammary gland fat in situ Fat pad.After inoculating cell, the 8th day starts to observe, and observes weekly once afterwards, mouse tumor is measured respectively using vernier caliper Major diameter a and minor axis b, and calculate gross tumor volume and tumor formation rate.Gross tumor volume calculation formula is 0.5*ab².When 6 weeks, place Dead mouse.

Shown in the testing result of gross tumor volume such as Fig. 4 (c), mouse is the 0th, 1,2,3,4,5,6 after 231-NC cells are inoculated with All gross tumor volumes are respectively 0.000 ± 0.000,3.398 ± 5.829,10.627 ± 10.152,32.637 ± 20.258, 60.116 ± 24.670,158.550 ± 59.933 and 331.362 ± 100.745 (unit mm³)；Mouse is in inoculation 231-sh4 The 0th after cell, 1,2,3,4,5,6 weeks gross tumor volumes be respectively 0.000 ± 0.000,0.000 ± 0.000,4.068 ± 6.957, 14.460 ± 20.532,13.208 ± 17.609,36.183 ± 48.657 and 96.543 ± 127.005 (unit mm³)；

Shown in the testing result of tumor formation rate such as Fig. 4 (d), the tumor formation rates of control cell 231-NC group mouse is apparently higher than 231- Sh4 groups.

The above results show：After striking low BTN3A2 and BTN3A3, tumor formation rate of the breast cancer cell in nude mouse, into knurl Volume is decreased obviously.Illustrate that BTN3A2 and BTN3A3 promotes tumour to be formed.

There are direct and specific interaction by embodiment 5, LSECtin and BTN3A2 and BTN3A3

There are direct and special interaction with BTN3A2 and BTN3A3 by adhesion experiment verification LSECtin

1st, BTN3A1, the structure of the carrier of BTN3A2, BTN3A3 are overexpressed

BTN3A1 sequences (sequence 6), BTN3A2 sequences (sequence 7), BTN3A3 sequences (sequence 8) are replaced respectively DNA fragmentation between I restriction enzyme site of Nde I and Xho of pIRES2-EGFP carriers (Clotech, 6029-1), is expressed respectively The carrier pIRES2-EGFP-BTN3A1 of BTN3A1, the pIRES2-EGFP-BTN3A2 for expressing BTN3A2, express BTN3A3's pIRES2-EGFP-BTN3A3。

2nd, the carrier pIRES2-EGFP-BTN3A1 of BTN3A1 will be expressed respectively, expresses the pIRES2-EGFP- of BTN3A2 BTN3A2, (country is real for pIRES2-EGFP-BTN3A3 and empty carrier pIRES2-EGFP transfection the BT474 cells of expression BTN3A3 Test cellular resources shared platform, 3111C0001CCC000129), after transfecting 36h, respectively obtain the cell for being overexpressed BTN3A1 BT474-BTN3A1, be overexpressed BTN3A2 cell BT474-BTN3A2, be overexpressed BTN3A3 cell BT474-BTN3A3 and It is overexpressed the cell BT474-EGFP of empty carrier.

3rd, each cell that collection step 2 obtains is digested, respectively employment source LSECtin albumen (R＆D, 2947-CL) and mouse Source LSECtin-Fc albumen and above-mentioned each cell adherence, and detect people source with mouse anti human LSECtin antibody CCB059 LSECtin adhesion rates, with anti-IgG (Biolegend, 405307) detection mouse source LSECtin adhesion rates, pass through flow cytometer detection Adhesion percentage.Adhesion experiment specific steps reference literature " Tang L, Yang J, Tang X, et al.The DC-SIGN family member LSECtin is a novel ligand of CD44 on activated T cells[J] .European journal of immunology,2010,40(4):1185-1191. " in method.

Adhesion experiment verify LSECtin and BTN3A3 there are result such as Fig. 5 (a) of direct and specific interaction and Shown in Fig. 5 (b).Wherein, shown in people source LSECtin adhesion results such as Fig. 5 (a), LSECtin and the cell for being overexpressed empty carrier BT474-EGFP does not adhere to (adhesion rate 3.579%), and the cell BT474-BTN3A1 with being overexpressed BTN3A1 does not adhere to (adhesion Rate is 0.775%) the weak adhesions (adhesion rate 42.33%) of cell BT474-BTN3A2 with being overexpressed BTN3A2, with overexpression The cell BT474-BTN3A3 of BTN3A3 is adhered to by force (adhesion rate 57.587%).Mouse source LSECtin-Fc adhesion results such as Fig. 5 (b) shown in, LSECtin does not adhere to (adhesion rate 0.967%), with being overexpressed with being overexpressed the cell BT474-EGFP of empty carrier The cell BT474-BTN3A1 of BTN3A1 does not adhere to (adhesion rate 1.598%), the cell BT474- with being overexpressed BTN3A2 BTN3A2 does not adhere to (adhesion rate 6.61%), and (adhesion rate 27.345%) is adhered to BT474-BTN3A3.

The above results illustrate, the BTN3A3 of people source and mouse source LSECtin and human tumor cells surface expression exist directly and There are strong interaction by the BTN3A3 of special strong interaction, people source LSECtin and human tumor cells surface expression.

Embodiment 6, LSECtin and BTN3A2 and BTN3A3 interactions promote the maintenance of tumour cell dryness

First, ball, which forms experiment, proves that LSECtin and BTN3A2 and BTN3A3 interactions promote the dimension of tumour cell dryness Hold

The present embodiment forms experiment by ball proves that LSECtin and BTN3A2 and BTN3A3 interactions promote tumour cell The maintenance of dryness.Comprise the following steps that：

1st, 2 in 231-sh3 cells, 231-sh4 cells and 231-NC cells, and 5 step 2 of embodiment are obtained respectively The cell BT474-BTN3A1 of the overexpression BTN3A1 obtained, the cell BT474-BTN3A2 for being overexpressed BTN3A2, be overexpressed Single cell suspension is made in the cell BT474-BTN3A3 of BTN3A3 and the cell BT474-EGFP of overexpression empty carrier, and the first generation is thin Born of the same parents are passed on 1000/mL bed boards with 20,000/mL bed boards.

2nd, respectively by above-mentioned each cell, B27 (Life, 17504044), bFGF (Sigam, SRP2092), EGF (Sigma, E9644), insulin (Sigma, I3536), heparin (sigma, 1235853) and DMEM/F12 serum free mediums mix After even, cultivating system is respectively obtained, concentration of each component in cultivating system is：B27(10ng/ml)、bFGF(20ng/ Ml), EGF (20ng/ml), insulin (5 μ g/ml), heparin (4 μ g/ml), after cultivating 7-10 days, calculated diameter is more than 75 μm Number of spheres is simultaneously taken pictures.

3rd, sphere is collected by centrifugation in 800rpm, and pancreatin (Gibico, 25300120) digestion, 40 μm of screen filtrations, carry out secondary Sphere forms experiment.

4th, adding the LSECitn that concentration is 100ng/ml into above-mentioned each cultivating system respectively stimulates tumour cell, point The post-stimulatory each cells of LSECitn are not obtained.

As a result as shown in Fig. 6 (a) and Fig. 6 (b), under the LSECtin irritaiting concentrations of 100ng, LSECtin can promote pair Photo cell 231-NC cell balls are formed；But it cannot promote to strike the 231-sh3 cells and 231-sh4 cells of low BTN3A2 and BTN3A3 Ball formed.Under the LSECtin irritaiting concentrations of 100ng, LSECtin cannot promote to be overexpressed the cell BT474- of empty carrier The ball of EGFP is formed；But it can promote to be overexpressed the cell BT474-BTN3A2 of BTN3A2, be overexpressed the cell of BTN3A3 The ball of BT474-BTN3A3 is formed.

2nd, the detection of dryness characteristic molecular expression

4 balls obtained in collection step one form 231-sh4 cells and 231-NC cells in experiment, are examined by qPCR Survey the expression change of tumor of breast dryness correlated characteristic molecule OCT4, NANOG, SOX2.DC-SIGN represents negative control, Control is unused LSECtin stimulations group, and 231-sh4 is the cell for striking low BTN3A3, and 231-NC is control cell.Primer sequence Row are as follows：OCT4：Up-GCTCGAGAAGGATGTGGTCC；Down-GTTGTGCATAGTCGCTGCT；NANOG：Up- TCTGGACACTGGCTGAATCCT；Down-CGCTGATTAGGCTCCAACCAT；SOX2：Up- GCTCGCAGACCTACATGAAC；Down-GGGAGGAAGAGGTAACCACA.

As a result as shown in Fig. 6 (c), under the LSECtin irritaiting concentrations of 100ng, LSECtin can promote dryness is crucial to turn Record the expression of the factor Oct4, Nanog and Sox；But the promotion effect then cannot after BTN3A3 is knocked out.

The above results illustrate that LSECtin and BTN3A2 and BTN3A3 interactions promote tumor progression and promote tumour thin The maintenance of born of the same parents' dryness.

Embodiment 7, LSECtin and BTN3A2 and BTN3A3 interactions promote tumor progression to rely in activation tumour cell STAT3 phosphorylations

First, LSECtin stimulates the breast cancer cell STAT3 phosphorylations of expression BTN3A3

4 of step 1 in embodiment 6 ball stimulated through LSECtin obtained is collected respectively forms sample：Strike low BTN3A3 231-sh3 cells (LSECitn-231-sh3), strike 231-sh4 cells (LSECitn-231-sh4), the cell of low BTN3A3 The ball stimulated without LSECtin obtained in the 3 of 6 step 1 of 231-NC (LSECitn-231-NC) and embodiment forms sample： Strike the 231-sh3 cells (231-sh3) of low BTN3A3, strike 231-sh4 cells (231-sh4), the cell 231-NC of low BTN3A3 (231-NC).Digested using pancreatin, 4 DEG C, after 1000rmp centrifugations, abandon supernatant, collect cell, and cell three is washed by PBS It is secondary.30min is cracked by RIPA lysates on ice, 12,000rmp centrifugations, take supernatant, obtain cell pyrolysis liquid.Pass through Stat Antibody Sampler Kit kits (Cell signaling technology, 9939) Western Blot detections are split The background level of STAT1, STAT3, STAT5, STAT6 in liquid are solved, passes through Phospho-Stat Antibody Sampler Kit The phosphorus of STAT1, STAT3, STAT5, STAT6 in kit (Cell signaling technology, 9914) detection lysate Acidifying is horizontal.Specific detection method is with reference to the specification in kit.

As a result as shown in Fig. 7 (a), under LSECtin is stimulated, the p- of the 231-NC cells of normal expression BTN3A2 and BTN3A3 The horizontal obvious up-regulations of STAT3；But strike the 231-sh3 cells (LSECitn-231-sh3) of low BTN3A2 and BTN3A3, strike it is low In the 231-sh4 cells (LSECitn-231-sh4) of BTN3A2 and BTN3A3, LSECtin cannot be stimulated in p-STAT3 levels Adjust；But regardless of whether striking low BTN3A3, other molecule STAT1, STAT5, STAT6 phosphorylation levels of STAT families are made without up-regulation With.

The above results illustrate that LSECtin can stimulate the horizontal up-regulations of p-STAT3 by interacting with BTN3A3.

2nd, LSECtin promotes the breast cancer cell ball of expression BTN3A2 and BTN3A3 to form dependence STAT3 phosphorylations

The ball obtained in the 4 of 6 step 1 of embodiment is collected respectively forms sample：Strike the cell 231-sh3 of low BTN3A3, strike The cell 231-sh4 of the low BTN3A3 and cell 231-NC for striking low BTN3A3, and the 3rd day after sample is collected adds STAT3 Inhibitor (selleck, S1155), the tenth day detection ball quantity of formation.

As a result as shown in Fig. 7 (b), after adding STAT3 inhibitor, LSECtin promotes normal expression BTN3A2 and BTN3A3 The ball Forming abilities of 231-NC cells substantially reduce；Striking 231-sh3 the and 231-sh4 cells of low BTN3A2 and BTN3A3 In, add STAT3 inhibitor and cause LSECtin to promote ball formation effect to be wholly absent.

The above results illustrate that LSECtin and BTN3A2 and the BTN3A3 interaction of breast cancer cell expression promote tumour Process depends on the STAT3 phosphorylation levels of cell interior.

Sequence table

<110>In INST OF EMISSION ＆ RADIATION M's Beijing proteome research The heart

<120>A kind of target spot of oncotherapy and its application

<160>8

<210>1

<211>293

<212>PRT

<213>Artificial sequence

<220>

<223>

<400>1

Met Asp Thr Thr Arg Tyr Ser Lys Trp Gly Gly Ser Ser Glu Glu Val

1 5 10 15

Pro Gly Gly Pro Trp Gly Arg Trp Val His Trp Ser Arg Arg Pro Leu

20 25 30

Phe Leu Ala Leu Ala Val Leu Val Thr Thr Val Leu Trp Ala Val Ile

35 40 45

Leu Ser Ile Leu Leu Ser Lys Ala Ser Thr Glu Arg Ala Ala Leu Leu

50 55 60

Asp Gly His Asp Leu Leu Arg Thr Asn Ala Ser Lys Gln Thr Ala Ala

65 70 75 80

Leu Gly Ala Leu Lys Glu Glu Val Gly Asp Cys His Ser Cys Cys Ser

85 90 95

Gly Thr Gln Ala Gln Leu Gln Thr Thr Arg Ala Glu Leu Gly Glu Ala

100 105 110

Gln Ala Lys Leu Met Glu Gln Glu Ser Ala Leu Arg Glu Leu Arg Glu

115 120 125

Arg Val Thr Gln Gly Leu Ala Glu Ala Gly Arg Gly Arg Glu Asp Val

130 135 140

Arg Thr Glu Leu Phe Arg Ala Leu Glu Ala Val Arg Leu Gln Asn Asn

145 150 155 160

Ser Cys Glu Pro Cys Pro Thr Ser Trp Leu Ser Phe Glu Gly Ser Cys

165 170 175

Tyr Phe Phe Ser Val Pro Lys Thr Thr Trp Ala Ala Ala Gln Asp His

180 185 190

Cys Ala Asp Ala Ser Ala His Leu Val Ile Val Gly Gly Leu Asp Glu

195 200 205

Gln Gly Phe Leu Thr Arg Asn Thr Arg Gly Arg Gly Tyr Trp Leu Gly

210 215 220

Leu Arg Ala Val Arg His Leu Gly Lys Val Gln Gly Tyr Gln Trp Val

225 230 235 240

Asp Gly Val Ser Leu Ser Phe Ser His Trp Asn Gln Gly Glu Pro Asn

245 250 255

Asp Ala Trp Gly Arg Glu Asn Cys Val Met Met Leu His Thr Gly Leu

260 265 270

Trp Asn Asp Ala Pro Cys Asp Ser Glu Lys Asp Gly Trp Ile Cys Glu

275 280 285

Lys Arg His Asn Cys

290

<210>2

<211>334

<212>PRT

<213>Artificial sequence

<220>

<223>

<400>2

Met Lys Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val

1 5 10 15

Ser Leu Leu Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser

20 25 30

Val Leu Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala

35 40 45

Asp Leu Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu

50 55 60

Leu Lys Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala

65 70 75 80

Asp Gly Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg

85 90 95

Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu Arg

100 105 110

Ile His Asn Val Thr Ala Ser Asp Ser Gly Lys Tyr Leu Cys Tyr Phe

115 120 125

Gln Asp Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala

130 135 140

Ala Leu Gly Ser Asn Leu His Val Glu Val Lys Gly Tyr Glu Asp Gly

145 150 155 160

Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro Gln

165 170 175

Ile Gln Trp Ser Asn Ala Lys Gly Glu Asn Ile Pro Ala Val Glu Ala

180 185 190

Pro Val Val Ala Asp Gly Val Gly Leu Tyr Glu Val Ala Ala Ser Val

195 200 205

Ile Met Arg Gly Gly Ser Gly Glu Gly Val Ser Cys Ile Ile Arg Asn

210 215 220

Ser Leu Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile Ala Asp Pro

225 230 235 240

Phe Phe Arg Ser Ala Gln Pro Trp Ile Ala Ala Leu Ala Gly Thr Leu

245 250 255

Pro Ile Leu Leu Leu Leu Leu Ala Gly Ala Ser Tyr Phe Leu Trp Arg

260 265 270

Gln Gln Lys Glu Ile Thr Ala Leu Ser Ser Glu Ile Glu Ser Glu Gln

275 280 285

Glu Met Lys Glu Met Gly Tyr Ala Ala Thr Glu Arg Glu Ile Ser Leu

290 295 300

Arg Glu Ser Leu Gln Glu Glu Leu Lys Arg Lys Lys Ile Gln Tyr Leu

305 310 315 320

Thr Arg Gly Glu Glu Ser Ser Ser Asp Thr Asn Lys Ser Ala

325 330

<210>3

<211>584

<212>PRT

<213>Artificial sequence

<220>

<223>

<400>3

Met Lys Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val

1 5 10 15

Ser Leu Phe Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser

20 25 30

Val Leu Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala

35 40 45

Asp Leu Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu

50 55 60

Leu Arg Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala

65 70 75 80

Asp Gly Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg

85 90 95

Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu Arg

100 105 110

Ile His Asn Val Thr Ala Ser Asp Ser Gly Lys Tyr Leu Cys Tyr Phe

115 120 125

Gln Asp Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala

130 135 140

Ala Leu Gly Ser Asp Leu His Ile Glu Val Lys Gly Tyr Glu Asp Gly

145 150 155 160

Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro Gln

165 170 175

Ile Lys Trp Ser Asp Thr Lys Gly Glu Asn Ile Pro Ala Val Glu Ala

180 185 190

Pro Val Val Ala Asp Gly Val Gly Leu Tyr Ala Val Ala Ala Ser Val

195 200 205

Ile Met Arg Gly Ser Ser Gly Gly Gly Val Ser Cys Ile Ile Arg Asn

210 215 220

Ser Leu Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile Ala Asp Pro

225 230 235 240

Phe Phe Arg Ser Ala Gln Pro Trp Ile Ala Ala Leu Ala Gly Thr Leu

245 250 255

Pro Ile Ser Leu Leu Leu Leu Ala Gly Ala Ser Tyr Phe Leu Trp Arg

260 265 270

Gln Gln Lys Glu Lys Ile Ala Leu Ser Arg Glu Thr Glu Arg Glu Arg

275 280 285

Glu Met Lys Glu Met Gly Tyr Ala Ala Thr Glu Gln Glu Ile Ser Leu

290 295 300

Arg Glu Lys Leu Gln Glu Glu Leu Lys Trp Arg Lys Ile Gln Tyr Met

305 310 315 320

Ala Arg Gly Glu Lys Ser Leu Ala Tyr His Glu Trp Lys Met Ala Leu

325 330 335

Phe Lys Pro Ala Asp Val Ile Leu Asp Pro Asp Thr Ala Asn Ala Ile

340 345 350

Leu Leu Val Ser Glu Asp Gln Arg Ser Val Gln Arg Ala Glu Glu Pro

355 360 365

Arg Asp Leu Pro Asp Asn Pro Glu Arg Phe Glu Trp Arg Tyr Cys Val

370 375 380

Leu Gly Cys Glu Asn Phe Thr Ser Gly Arg His Tyr Trp Glu Val Glu

385 390 395 400

Val Gly Asp Arg Lys Glu Trp His Ile Gly Val Cys Ser Lys Asn Val

405 410 415

Glu Arg Lys Lys Gly Trp Val Lys Met Thr Pro Glu Asn Gly Tyr Trp

420 425 430

Thr Met Gly Leu Thr Asp Gly Asn Lys Tyr Arg Ala Leu Thr Glu Pro

435 440 445

Arg Thr Asn Leu Lys Leu Pro Glu Pro Pro Arg Lys Val Gly Ile Phe

450 455 460

Leu Asp Tyr Glu Thr Gly Glu Ile Ser Phe Tyr Asn Ala Thr Asp Gly

465 470 475 480

Ser His Ile Tyr Thr Phe Pro His Ala Ser Phe Ser Glu Pro Leu Tyr

485 490 495

Pro Val Phe Arg Ile Leu Thr Leu Glu Pro Thr Ala Leu Thr Ile Cys

500 505 510

Pro Ile Pro Lys Glu Val Glu Ser Ser Pro Asp Pro Asp Leu Val Pro

515 520 525

Asp His Ser Leu Glu Thr Pro Leu Thr Pro Gly Leu Ala Asn Glu Ser

530 535 540

Gly Glu Pro Gln Ala Glu Val Thr Ser Leu Leu Leu Pro Ala His Pro

545 550 555 560

Gly Ala Glu Val Ser Pro Ser Ala Thr Thr Asn Gln Asn His Lys Leu

565 570 575

Gln Ala Arg Thr Glu Ala Leu Tyr

580

<210>4

<211>21bp

<212>DNA

<213>Artificial sequence

<220>

<223>

<400>4

gccacagatg gatctcatat c 21

<210>5

<211>21bp

<212>DNA

<213>Artificial sequence

<220>

<223>

<400>5

cccttctgca acaaccaatc a 21

<210>6

<211>1542bp

<212>DNA

<213>Artificial sequence

<220>

<223>

<400>6

atgaaaatgg caagtttcct ggccttcctt ctgctcaact ttcgtgtctg cctccttttg 60

cttcagctgc tcatgcctca ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120

ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180

gagaccatgg agctgaagtg ggtgagttcc agcctaaggc aggtggtgaa cgtgtatgca 240

gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300

cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360

agtggaaagt acttgtgtta tttccaagat ggtgacttct atgaaaaagc cctggtggag 420

ctgaaggttg cagcactggg ttctgatctt cacgttgatg tgaagggtta caaggatgga 480

gggatccatc tggagtgcag gtccactggc tggtaccccc aaccccaaat acagtggagc 540

aacaacaagg gagagaacat cccgactgtg gaagcacctg tggttgcaga cggagtgggc 600

ctgtatgcag tagcagcatc tgtgatcatg agaggcagct ctggggaggg tgtatcctgt 660

accatcagaa gttccctcct cggcctggaa aagacagcca gcatttccat cgcagacccc 720

ttcttcagga gcgcccagag gtggatcgcc gccctggcag ggaccctgcc tgtcttgctg 780

ctgcttcttg ggggagccgg ttacttcctg tggcaacagc aggaggaaaa aaagactcag 840

ttcagaaaga aaaagagaga gcaagagttg agagaaatgg catggagcac aatgaagcaa 900

gaacaaagca caagagtgaa gctcctggag gaactcagat ggagaagtat ccagtatgca 960

tctcggggag agagacattc agcctataat gaatggaaaa aggccctctt caagcctgcg 1020

gatgtgattc tggatccaaa aacagcaaac cccatcctcc ttgtttctga ggaccagagg 1080

agtgtgcagc gtgccaagga gccccaggat ctgccagaca accctgagag atttaattgg 1140

cattattgtg ttctcggctg tgagagcttc atatcaggga gacattactg ggaggtggag 1200

gtaggggaca ggaaagagtg gcatataggg gtgtgcagta agaatgtgca gagaaaaggc 1260

tgggtcaaaa tgacacctga gaatggattc tggactatgg ggctgactga tgggaataag 1320

tatcggactc taactgagcc cagaaccaac ctgaaacttc ctaagccccc taagaaagtg 1380

ggggtcttcc tggactatga gactggagat atctcattct acaatgctgt ggatggatcg 1440

catattcata ctttcctgga cgtctccttc tctgaggctc tatatcctgt tttcagaatt 1500

ttgaccttgg agcccacggc cctgactatt tgtccagcgt ga 1542

<210>7

<211>1005bp

<212>DNA

<213>Artificial sequence

<220>

<223>

<400>7

atgaaaatgg caagttccct ggctttcctt ctgctcaact ttcatgtctc cctcctcttg 60

gtccagctgc tcactccttg ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120

ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180

gagaccatgg agctgaagtg ggtaagttcc agcctaaggc aggtggtgaa cgtgtatgca 240

gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300

cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360

agtggaaagt acttgtgtta tttccaagat ggtgacttct atgaaaaagc cctggtggag 420

ctgaaggttg cagcactggg ttctaatctt cacgtcgaag tgaagggtta tgaggatgga 480

gggatccatc tggagtgcag gtccaccggc tggtaccccc aaccccaaat acagtggagc 540

aacgccaagg gagagaacat cccagctgtg gaagcacctg tggttgcaga tggagtgggc 600

ctatatgaag tagcagcatc tgtgatcatg agaggcggct ccggggaggg tgtatcctgc 660

atcatcagaa attccctcct cggcctggaa aagacagcca gcatttccat cgcagacccc 720

ttcttcagga gcgcccagcc ctggatcgca gccctggcag ggaccctgcc tatcttgctg 780

ctgcttctcg ccggagccag ttacttcttg tggagacaac agaaggaaat aactgctctg 840

tccagtgaga tagaaagtga gcaagagatg aaagaaatgg gatatgctgc aacagagcgg 900

gaaataagcc taagagagag cctccaggag gaactcaaga ggaaaaaaat ccagtacttg 960

actcgtggag aggagtcttc gtccgatacc aataagtcag cctga 1005

<210>8

<211>1755bp

<212>DNA

<213>Artificial sequence

<220>

<223>

<400>8

atgaaaatgg caagttccct ggctttcctt ctgctcaact ttcatgtctc cctcttcttg 60

gtccagctgc tcactccttg ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120

ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180

gagaccatgg agctgaggtg ggtgagttcc agcctaaggc aggtggtgaa cgtgtatgca 240

gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300

cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360

agtggaaagt acttgtgtta tttccaagat ggtgacttct acgaaaaagc cctggtggag 420

ctgaaggttg cagcattggg ttctgatctt cacattgaag tgaagggtta tgaggatgga 480

gggatccatc tggagtgcag gtccactggc tggtaccccc aaccccaaat aaagtggagc 540

gacaccaagg gagagaacat cccggctgtg gaagcacctg tggttgcaga tggagtgggc 600

ctgtatgcag tagcagcatc tgtgatcatg agaggcagct ctggtggggg tgtatcctgc 660

atcatcagaa attccctcct cggcctggaa aagacagcca gcatatccat cgcagacccc 720

ttcttcagga gcgcccagcc ctggatcgcg gccctggcag ggaccctgcc tatctcgttg 780

ctgcttctcg caggagccag ttacttcttg tggagacaac agaaggaaaa aattgctctg 840

tccagggaga cagaaagaga gcgagagatg aaagaaatgg gatacgctgc aacagagcaa 900

gaaataagcc taagagagaa gctccaggag gaactcaagt ggaggaaaat ccagtacatg 960

gctcgtggag agaagtcttt ggcctatcat gaatggaaaa tggccctctt caaacctgcg 1020

gatgtgattc tggatccaga cacggcaaac gccatcctcc ttgtttctga ggaccagagg 1080

agtgtgcagc gtgctgaaga gccgcgggat ctgccagaca accctgagag atttgaatgg 1140

cgttactgtg tccttggctg tgaaaacttc acatcaggga gacattactg ggaggtggaa 1200

gtgggggaca gaaaagagtg gcatattggg gtatgtagta agaacgtgga gaggaaaaaa 1260

ggttgggtca aaatgacacc ggagaacgga tactggacta tgggcctgac tgatgggaat 1320

aagtatcggg ctctcactga gcccagaacc aacctgaaac ttcctgagcc tcctaggaaa 1380

gtggggatct tcctggacta tgagactgga gagatctcgt tctataatgc cacagatgga 1440

tctcatatct acacctttcc gcacgcctct ttctctgagc ctctatatcc tgttttcaga 1500

attttgacct tggagcccac tgccctgacc atttgcccaa taccaaaaga agtagagagt 1560

tcccccgatc ctgacctagt gcctgatcat tccctggaga caccactgac cccgggctta 1620

gctaatgaaa gtggggagcc tcaggctgaa gtaacatctc tgcttctccc tgcccaccct 1680

ggagctgagg tctccccttc tgcaacaacc aatcagaacc ataagctaca ggcacgcact 1740

gaagcacttt actga 1755

Claims (10)

1. suppress BTN3A expression and/or active material in the product with least one of following (1)-(5) is prepared Application：

(1) treatment and/or pre- preventing tumor；

(2) growth of tumour cell is suppressed；

(3) maintenance or promotion of tumour cell dryness are suppressed；

(4) expression of tumour cell dryness correlated characteristic molecule is suppressed；

(5) inside tumor cells STAT3 phosphorylations are suppressed；

The BTN3A is following a1) or a2)：

a1)BTN3A3；

A2) BTN3A2 and BTN3A3.

2. application according to claim 1, it is characterised in that：

The material of the suppression BTN3A expression and/or activity is following any：Disturb the RNA of BTN3A2 and BTN3A3 expression Molecule, anti-LSECtin antibody, LSECtin micromolecular inhibitors, LSECtin soluble proteins, the RNA of interference LSECtin expression Molecule, anti-BTN3A2 antibody, BTN3A2 micromolecular inhibitors, BTN3A2 soluble proteins, the RNA of interference BTN3A2 expression divide Sub, anti-BTN3A3 antibody, BTN3A3 micromolecular inhibitors, BTN3A3 soluble proteins and the RNA molecule of interference BTN3A3 expression.

3. application according to claim 1 or 2, it is characterised in that：

The RNA molecule of interference BTN3A2 and the BTN3A3 expression and the RNA molecule of interference BTN3A3 expression are as follows b1)-b4)：

B1) the shRNA molecule shown in sequence 4；

B2) sequence 4 is deleted or increases or change one or several nucleotide, and with the nucleotide of 4 identical function of sequence；

B3) the shRNA molecule shown in sequence 5；

B4) sequence 5 is deleted or increases or change one or several nucleotide, and with the nucleotide of 5 identical function of sequence；

And/or the tumour cell dryness correlated characteristic molecule is Oct4 genes and/or Nanog genes and/or Sox genes；

And/or the growth for suppressing tumour cell is embodied in the tumor formation rate for reducing tumour cell and/or reduces tumour cell Volume.

4. according to any application in claim 1-3, it is characterised in that：

The product is medicine；

And/or

The tumour is following c1) or c2)：

C1) the tumour of BTN3A3 expression；

C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression；

The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.

5. a kind of product, for its active ingredient to suppress the material of BTN3A expression and/or activity, the purposes of the product is as follows (1) at least one of-(5)：

(1) treatment and/or pre- preventing tumor；

(2) growth of tumour cell is suppressed；

(3) maintenance or promotion of tumour cell dryness are suppressed；

(4) expression of tumour cell dryness correlated characteristic molecule is suppressed；

(5) inside tumor cells STAT3 phosphorylations are suppressed；

The BTN3A is following a1) or a2)：

a1)BTN3A3；

A2) BTN3A2 and BTN3A3.

6. product according to claim 5, it is characterised in that：The material of the suppression BTN3A expression and/or activity is such as Under it is any：Disturb BTN3A2 and BTN3A3 expression RNA molecule, anti-LSECtin antibody, LSECtin micromolecular inhibitors, LSECtin soluble proteins, interference LSECtin expression RNA molecule, anti-BTN3A2 antibody, BTN3A2 micromolecular inhibitors, BTN3A2 soluble proteins, interference BTN3A2 expression RNA molecule, anti-BTN3A3 antibody, BTN3A3 micromolecular inhibitors, BTN3A3 soluble proteins and the RNA molecule of interference BTN3A3 expression.

7. the product according to claim 5 or 6, it is characterised in that：

The RNA molecule of interference BTN3A2 and the BTN3A3 expression and the RNA molecule of interference BTN3A3 expression are as follows b1)-b4)：

B1) the shRNA molecule shown in sequence 4；

B2) sequence 4 is deleted or increases or change one or several nucleotide, and with the nucleotide of 4 identical function of sequence；

B3) the shRNA molecule shown in sequence 5；

B4) sequence 5 is deleted or increases or change one or several nucleotide, and with the nucleotide of 5 identical function of sequence；

And/or the tumour cell dryness correlated characteristic molecule is Oct4 genes and/or Nanog genes and/or Sox genes；

And/or the growth for suppressing tumour cell is embodied in the tumor formation rate for reducing tumour cell and/or reduces tumour cell Volume.

8. according to any product in claim 5-7, it is characterised in that：

The product is medicine；

And/or

The tumour is following c1) or c2)：

C1) the tumour of BTN3A3 expression；

C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression；

The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.

Applications of the 9.BTN3A2 and/or BTN3A3 as target spot in immunotherapy of tumors；

And/or applications of the BTN3A2 and/or BTN3A3 as target spot in developing or designing immunotherapy of tumors medicine.

10. application according to claim 9, it is characterised in that：

The product is medicine；

And/or

The tumour is following c1) or c2)：

C1) the tumour of BTN3A3 expression；

C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression；

The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.